The Menarini Group announced that the European Commission (EC) has granted a marketing authorization, for Elzonris (tagraxofusp) as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare, aggressive hematologic malignancy with dismal outcomes.
The FDA approved Elzonris (tagraxofusp-erzs) infusion from Stemline Therapeutics, for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in...
Stemline Therapeutics, Inc.announced an agreement with the FDA on the registration pathway for SL 401 in blastic plasmacytoid dendritic cell...
The Menarini Group announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion on the approval of Elzonris (tagraxofusp) as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic malignancy with dismal outcomes.
Stemline Therapeutics, Inc. , a biopharmaceutical company focused on the development and potential commercialization of novel oncology therapeutics, announced that...
Stemline Therapeutics announced that it has completed submission of a rolling Biologics License Application (BLA) to the FDA for Elzonris...
Psoriasis vulgaris, a type-1 cytokine-mediated chronic skin disease, can be treated successfully with fumaric acid esters (FAE).
Objective: We sought to analyze the effects of anti-TNF-α treatment on TNF-α(+) cells in the skin and blood of patients with psoriasis.
Fumarates improve multiple sclerosis (MS) and psoriasis, two diseases in which both IL-12 and IL-23 promote pathogenic T helper (Th) cell differentiation.
Biogen Inc. has announced that The New England Journal of Medicine (NEJM) has published positive results from the cutaneous lupus erythematosus (CLE) portion of the two-part Phase II LILAC study (Part B) evaluating litifilimab (known as BIIB059), an investigational drug for the treatment of lupus. Litifilimab met its primary endpoint by demonstrating superior efficacy to placebo in reducing skin disease activity.